Year All2026202520242023 Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis March 3, 2026 Read more Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis January 20, 2026 Read more Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF November 6, 2025 Read more Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis November 3, 2025 Read more Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis October 9, 2025 Read more Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis September 17, 2025 Read more Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis August 19, 2025 Read more Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 August 14, 2025 Read more Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing July 30, 2025 Read more Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders June 24, 2025 Read more
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis March 3, 2026 Read more
Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis January 20, 2026 Read more
Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF November 6, 2025 Read more
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis November 3, 2025 Read more
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis October 9, 2025 Read more
Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis September 17, 2025 Read more
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis August 19, 2025 Read more
Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 August 14, 2025 Read more
Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing July 30, 2025 Read more
